SCOPUS 정보 검색 플랫폼

Journal of Endotoxin Research

Volumn 5, Issue 3, 1999, Pages 174-176

Blocking IL-1 and TNF

(1) Dinarello, Charles A a

a UNIVERSITY OF COLORADO (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

CONFERENCE PAPER; HUMAN; IMMUNOTHERAPY; NONHUMAN; SEPTIC SHOCK;

ANIMALIA; ESCHERICHIA COLI; ORYCTOLAGUS CUNICULUS; PAPIO;

EID: 0032821135 PISSN: 09680519 EISSN: None Source Type: Journal
DOI: 10.1179/096805199101531606 Document Type: Conference Paper

Times cited : (2)

References (12)

1
- 0024822793
- Antibodies to cachectin/tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia
- Fong Y, Tracey KJ, Moldawer LL, Hesse DG, Manogue KB, Kenney JS et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia. J Exp Med 1989; 170: 1627-1633.
- (1989) J Exp Med , vol.170 , pp. 1627-1633
- Fong, Y.¹ Tracey, K.J.² Moldawer, L.L.³ Hesse, D.G.⁴ Manogue, K.B.⁵ Kenney, J.S.⁶

2
- 0025852720
- A specific receptor antagonist for interleukin-1 prevents Escherichia coli-induced shock
- Wakabayashi G, Gelfand JA, Burke JF, Thompson RC, Dinarello CA. A specific receptor antagonist for interleukin-1 prevents Escherichia coli-induced shock. FASEB J 1991; 5: 338-343.
- (1991) FASEB J , vol.5 , pp. 338-343
- Wakabayashi, G.¹ Gelfand, J.A.² Burke, J.F.³ Thompson, R.C.⁴ Dinarello, C.A.⁵

3
- 0015878917
- Biological effects of bacterial endotoxins in man
- Wolff SM. Biological effects of bacterial endotoxins in man. J Infect Dis 1973; 128 (Suppl): 733-758.
- (1973) J Infect Dis , vol.128 , Issue.SUPPL. , pp. 733-758
- Wolff, S.M.¹

4
- 0023926860
- Sensitization and desensitization to lethal effects of tumor necrosis factor and IL-1
- Wallach D, Holtmann H, Engelmann H, Nophar Y. Sensitization and desensitization to lethal effects of tumor necrosis factor and IL-1. J Immunol 1988; 140: 2994-2999.
- (1988) J Immunol , vol.140 , pp. 2994-2999
- Wallach, D.¹ Holtmann, H.² Engelmann, H.³ Nophar, Y.⁴

5
- 0008945388
- Biological basis for interleukin-1 in disease
- Dinarello CA. Biological basis for interleukin-1 in disease. Blood 1996; 87: 20952147.
- (1996) Blood , vol.87 , pp. 20952147
- Dinarello, C.A.¹

6
- 0028143211
- Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
- Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-1110.
- (1994) Lancet , vol.344 , pp. 1105-1110
- Elliott, M.J.¹ Maini, R.N.² Feldmann, M.³ Kalden, J.R.⁴ Antoni, C.⁵ Smolen, J.S.⁶

7
- 0000658854
- A dose- and regimen-ranging study of IL-1 receptor antagonist in patients with rheumatoid arthritis
- Lebsack ME, Paul CC, Martindale JJ, Catalano MA. A dose-and regimen-ranging study of IL-1 receptor antagonist in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1993; 36: S39.
- (1993) Arthritis Rheum , vol.36
- Lebsack, M.E.¹ Paul, C.C.² Martindale, J.J.³ Catalano, M.A.⁴

8
- 0000168402
- Treatment with recombinant human interleukin-1 receptor antagonist in rheumatoid arthritis: Results of a randomized, double-blind, placebo-controlled multicenter trial
- Bresnihan B, Lookabaugh J, Witt K, Musikic P. Treatment with recombinant human interleukin-1 receptor antagonist in rheumatoid arthritis: results of a randomized, double-blind, placebo-controlled multicenter trial [abstract]. Arthritis Rheum 1996; 39: S73.
- (1996) Arthritis Rheum , vol.39
- Bresnihan, B.¹ Lookabaugh, J.² Witt, K.³ Musikic, P.⁴

9
- 0000002243
- Recombinant human interleukin-1 receptor antagonist reduces the rate of joint erosion in rheumatoid arthritis
- Watt I, Cobby M. Recombinant human interleukin-1 receptor antagonist reduces the rate of joint erosion in rheumatoid arthritis [abstract]. Arthritis Rheum 1996; 39: S123.
- (1996) Arthritis Rheum , vol.39
- Watt, I.¹ Cobby, M.²

10
- 0029050742
- Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
- van Dullemen HM, van Deventer SJH, Hommes DW, Bijl HA, Jansen J, Tytgat GN et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129-135.
- (1995) Gastroenterology , vol.109 , pp. 129-135
- Van Dullemen, H.M.¹ Van Deventer, S.J.H.² Hommes, D.W.³ Bijl, H.A.⁴ Jansen, J.⁵ Tytgat, G.N.⁶

11
- 0028086480
- Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease
- Antin JH, Weinstein HJ, Guinan EC, McCarthy P, Bierer BE, Gilliland DG et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 1994; 84: 1342-1348
- (1994) Blood , vol.84 , pp. 1342-1348
- Antin, J.H.¹ Weinstein, H.J.² Guinan, E.C.³ McCarthy, P.⁴ Bierer, B.E.⁵ Gilliland, D.G.⁶

12
- 0030746482
- Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment
- Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 1997; 25: 1095-1100.
- (1997) Crit Care Med , vol.25 , pp. 1095-1100
- Zeni, F.¹ Freeman, B.² Natanson, C.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.